Fig 1: EVT801 reduces circulation of chemokines and MDSCs in the blood. A, Tumor volume progression over time of orthotopic 4T1 tumors in BALB/c mice in presence of vehicle, isotype control, anti-CTLA-4 (twice per week), 30 mg/kg EVT801 (twice per day), or a combination of anti-PD-1 and EVT801. B, Individual plasma concentrations of CCL3/MIP-1α, CCL4/MIP-1β, and CCL5/Rantes at endpoint for each of the four treatment groups. C, Individual blood concentration of CD124+ PMN-MDSCs at endpoint for each of the four treatment groups. D, Individual blood concentration of CD124+ M-MDSCs at endpoint for each of the four treatment groups. E, Individual blood concentration of CD8+ T cells at endpoint for each of the four treatment groups. F, Correlation between circulating CCL4 and PMN-MDSC levels. G, Correlation between circulating CCL4 and tumor weight. H, Inverse correlation between CD8+ T-cell/PMN-MDSC ratio and tumor weight.